Low-Dose Rivaroxaban Associated with Reduced Thromboembolic Event Mortality - MD Magazine

Low-Dose Rivaroxaban Associated with Reduced Thromboembolic Event Mortality  MD Magazine

New COMMANDER HF post hoc data shows more evidence the blood-thinning therapy has some effect on potentially deadly cardiovascular events.



Comments

Post a Comment

Popular posts from this blog

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma - Global Banking And Finance Review

Celgene Corporation Announces POMALYST® Granted Breakthrough Therapy Designation from FDA for HIV-Positive and Negative Kaposi Sarcoma    Global Banking And Finance Review Celgene Corporation (NASDAQ:CELG) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Read more